Skip to main content

Table 1 Characteristics of patients

From: Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae

Characteristic Total Complete cohort (N = 180) Cohort adjusted by PSMa
BLICs Carbapenems P BLICs Carbapenems P
N (%) 180 N = 114 (63.3%) N = 66 (36.7%)   N = 63 (59.4%) N = 43 (40.6%)  
Age, years
 Mean (SD) 59.3 (13.1) 61.7 (12.4) 55.2 (13.3) 0.001 58.2 (12.3) 55.7 (11.9) 0.469
Sex, N (%)
 Male 91 (50.6) 58 (50.9) 33 (50.0) 0.910 30(47.6) 22 (51.2) 0.720
 Female 89 (49.4) 56 (49.1) 33 (50.0)   33 (52.4) 21 (48.8)  
Acquisition, N (%)
 Hospital-acquired 117 (65.0) 71 (62.3) 46 (69.7) 0.315 41 (65.1) 32 (74.4) 0.308
 Community-associated 63 (35.0) 43 (37.7) 20 (30.3)   22 (34.9) 11 (25.6)  
Length, median (IQR)
 Length of hospital stay 20.5 (12–30) 18 (11–28) 24 (14–32) 0.016 20 (11–29) 25 (14–32) 0.055
Severity of condition, median (IQR)
 aCCI 3 (2–5) 4 (2–6) 3 (2–4.25) 0.036 3 (2–5) 3 (2–4) 0.797
 Pitt bacteraemia score 1 (0–2.75) 1 (0–2) 2 (1–4) 0.000 1 (0–2) 1 (0–2.5) 0.995
 SOFA score 3 (2–6) 3 (1–5) 5 (2.75–9) 0.000 4 (2–6) 3 (1.3–6) 0.517
Underlying diseases, N (%)
 Immune compromise 35 (19.4) 15 (13.2) 20 (30.3) 0.005 13 (20.6) 13 (30.2) 0.259
 Leukaemia 13 (7.2) 3 (2.6) 10 (15.2) 0.002 3 (4.8) 7 (16.3) 0.086
 Arrhythmia 16 (8.9) 11 (9.6) 5 (7.6) 0.638 5 (7.9) 3 (7.0) 1.000
 Hypertension 42 (23.2) 27 (23.7) 15 (22.7) 0.884 12 (19.0) 7 (16.3) 0.970
 Diabetes 20 (11.1) 14 (12.3) 6 (9.1) 0.512 6 (9.5) 2 (4.7) 0.469
 Hypoproteinaemia 47 (26.1) 32 (28.1) 15 (22.7) 0.432 16 (25.4) 9 (20.9) 0.820
Bacteria, N (%)     0.448    0.778
 Escherichia coli 147 (81.7) 95 (83.3) 52 (78.8)   54 (85.7) 36 (83.7)  
 Klebsiella pneumoniae 33 (18.3) 19 (16.7) 14 (21.2)   9 (14.3) 7 (16.3)  
Empirical treatment, N (%)     0.268    0.154
 Appropriate 159 (88.3) 103(90.4) 56 (84.8)   60 (95.2) 37 (86.0)  
 Inappropriate 21 (11.7) 11 (9.6) 10 (15.2)   3 (4.8) 6 (14.0)  
  1. aAdjustment using propensity score matching, covariates including age, length of hospital stay, aCCI, Pitt bacteraemia score, SOFA score, immune compromise, and leukaemia